Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clin Mol Hepatol 2016;22(3):382-389. Published online September 25, 2016
Background/Aims Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response.
Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal.
Result s: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log10 IU/mL (n=28), respectively.
Conclusions The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log10 IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration.
Citations
Citations to this article as recorded by
Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries Ben Kang, Dae Yong Yi, Byung-Ho Choe Frontiers in Pediatrics.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Drug Discovery Study Aimed at a Functional Cure for HBV Takehisa Watanabe, Sanae Hayashi, Yasuhito Tanaka Viruses.2022; 14(7): 1393. CrossRef
Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu Nutrients.2022; 14(14): 2790. CrossRef
Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie‐Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis Liver International.2021; 41(1): 48. CrossRef
Advances in treatment and prevention of hepatitis B Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson Gut.2021; : gutjnl-2020-323979. CrossRef
Advances in treatment and prevention of hepatitis B Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B Florian van Bömmel, Thomas Berg Hepatology Communications.2021; 5(10): 1632. CrossRef
Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B Do Seon Song, Jeong Won Jang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Clinical Infectious Diseases.2021; 73(4): e892. CrossRef
Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B Margarita Papatheodoridi, George Papatheodoridis Cells.2020; 9(2): 493. CrossRef
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson Viruses.2020; 12(9): 934. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao BMC Infectious Diseases.2020;[Epub] CrossRef
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg‐negative chronic hepatitis B Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis Journal of Viral Hepatitis.2019; 26(6): 697. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
New Biomarkers of Chronic Hepatitis B Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen Gut and Liver.2019; 13(6): 589. CrossRef
Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B Florian van Bömmel, Thomas Berg Liver International.2018; 38(S1): 90. CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans M. J. Tong, C. Q. Pan, S.‐H. B. Han, D. S.‐K. Lu, S. Raman, K.‐Q. Hu, J. K. Lim, H. W. Hann, A. D. Min Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181. CrossRef
First
Prev
